ZA993200B - Use of nanodispersions in pharmaceutical end formulations. - Google Patents

Use of nanodispersions in pharmaceutical end formulations.

Info

Publication number
ZA993200B
ZA993200B ZA9903200A ZA993200A ZA993200B ZA 993200 B ZA993200 B ZA 993200B ZA 9903200 A ZA9903200 A ZA 9903200A ZA 993200 A ZA993200 A ZA 993200A ZA 993200 B ZA993200 B ZA 993200B
Authority
ZA
South Africa
Prior art keywords
nanodispersions
pharmaceutical end
end formulations
formulations
pharmaceutical
Prior art date
Application number
ZA9903200A
Other languages
English (en)
Inventor
Andreas Werner Supersaxo
Hans Georg Weder
Dietmar Hueglin
Joachim Friedrich Roeding
Original Assignee
Ciba Sc Holding Ag
Vesifact Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Sc Holding Ag, Vesifact Ag filed Critical Ciba Sc Holding Ag
Publication of ZA993200B publication Critical patent/ZA993200B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA9903200A 1998-05-11 1999-05-10 Use of nanodispersions in pharmaceutical end formulations. ZA993200B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98810422 1998-05-11

Publications (1)

Publication Number Publication Date
ZA993200B true ZA993200B (en) 1999-11-11

Family

ID=8236078

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9903200A ZA993200B (en) 1998-05-11 1999-05-10 Use of nanodispersions in pharmaceutical end formulations.

Country Status (20)

Country Link
US (2) US7081253B2 (es)
EP (1) EP0956853B1 (es)
JP (1) JP4755742B2 (es)
KR (1) KR100622285B1 (es)
CN (1) CN1220483C (es)
AR (1) AR019274A1 (es)
AT (1) ATE312597T1 (es)
AU (1) AU767896B2 (es)
BR (1) BRPI9902068B8 (es)
CZ (1) CZ166999A3 (es)
DE (1) DE59912910D1 (es)
ES (1) ES2253871T3 (es)
HU (1) HUP9901570A2 (es)
ID (1) ID22565A (es)
MY (1) MY133019A (es)
PL (1) PL332934A1 (es)
RU (1) RU2224505C2 (es)
SG (1) SG71923A1 (es)
TW (1) TWI241915B (es)
ZA (1) ZA993200B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9908309D0 (en) * 1999-04-12 1999-06-02 Phares Pharm Res Nv Lipid aggregate forming compositions and their use
FR2805761B1 (fr) * 2000-03-02 2002-08-30 Mainelab Nanocapsules lipidiques, procede de preparation et utilisation comme medicament
TW586945B (en) * 2001-01-12 2004-05-11 Novartis Ag Lens care product containing dexpanthenol
US20030113366A1 (en) * 2001-12-14 2003-06-19 Macgregor Alexander Reverse-micellar delivery system for controlled transportation and enhanced absorption of agents
AT6609U3 (de) * 2003-04-07 2004-04-26 Unipack Ges M B H Abfuell Und Verfahren zum herstellen einer klaren lecithin enthaltenden oralen zubereitung
ITMI20032019A1 (it) * 2003-10-17 2005-04-18 Fidia Farmaceutici Microemulsioni di retinoidi e composizioni farmaceutiche che le contengono
TWI350183B (en) * 2003-12-31 2011-10-11 Ind Tech Res Inst A liposome and a preparation method
SG173326A1 (en) * 2004-06-04 2011-08-29 Camurus Ab Liquid depot formulations
US20060198891A1 (en) * 2004-11-29 2006-09-07 Francois Ravenelle Solid formulations of liquid biologically active agents
WO2007011030A1 (ja) * 2005-07-21 2007-01-25 National Institute For Materials Science 薬物吸入デバイス
US7745400B2 (en) 2005-10-14 2010-06-29 Gregg Feinerman Prevention and treatment of ocular side effects with a cyclosporin
US9839667B2 (en) 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
NZ572601A (en) 2006-03-29 2012-03-30 Univ Wayne State Liposomal nanoparticles and other formulations of fenretinide for use in therapy and drug delivery
JP4840031B2 (ja) 2006-08-31 2011-12-21 ソニー株式会社 ナビゲーション装置、ナビゲーション処理方法及びナビゲーション処理プログラム
EP1938801A1 (en) * 2006-12-22 2008-07-02 Biofrontera Bioscience GmbH Nanoemulsion
CL2008000037A1 (es) * 2007-01-16 2008-10-10 Bayer Consumer Care Ag Solucion coloidal que comprende al menos un ingrediente activo, al menos una molecula formadora de membrana y al menos un componente espumante; procedimiento para fabricar la solucion coloidal; y su uso para tratar trastornos dermatologicos.
WO2008135828A2 (en) 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
WO2008135855A2 (en) 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer
US9545384B2 (en) 2007-06-04 2017-01-17 Bend Research, Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate
EP2162120B1 (en) 2007-06-04 2016-05-04 Bend Research, Inc Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
EP2231169B1 (en) 2007-12-06 2016-05-04 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
US9233078B2 (en) 2007-12-06 2016-01-12 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer
CN100536826C (zh) * 2007-12-28 2009-09-09 清华大学 一种绵羊油纳米乳液及其制备方法和应用
US20110033545A1 (en) * 2009-08-06 2011-02-10 Absize, Inc. Topical pharmaceutical preparations having both a nanoparticle solution and a nanoparticle suspension and methods for the treatment of acute and chronic pain therewith
FR2949063B1 (fr) * 2009-08-11 2011-09-30 Pf Medicament Composition pharmaceutique comprenant un ester de dha destinee a etre administree par voie parenterale
DE202010004750U1 (de) 2010-04-09 2011-10-11 Biofrontera Bioscience Gmbh Pharmazeutische oder/und kosmetische Zusammensetzung zur Behandlung der Haut
CN102277748A (zh) * 2010-06-12 2011-12-14 罗莱家纺股份有限公司 纳米维生素微胶囊整理剂的使用方法
KR101494594B1 (ko) * 2011-08-30 2015-02-23 주식회사 종근당 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
KR101586789B1 (ko) 2012-12-28 2016-01-19 주식회사 종근당 양이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
KR101586791B1 (ko) 2012-12-28 2016-01-19 주식회사 종근당 ＧｎＲＨ 유도체의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
KR101586790B1 (ko) 2012-12-28 2016-01-19 주식회사 종근당 음이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
EP3583954A1 (en) * 2018-06-19 2019-12-25 neubourg skin care GmbH Nanodispersions of birch bark extract, electrospun fibers containing such nanodispersions and their use for the treatment of wounds
CN111388744B (zh) * 2020-01-15 2021-05-18 华中科技大学 一种凝胶贮库及其制法与制备术后止血制剂的应用
AU2021299156A1 (en) 2020-06-30 2023-01-19 Chong Kun Dang Pharmaceutical Corp. Injectable composition comprising GnRH analogue

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3150990A1 (de) 1981-12-23 1983-06-30 A. Nattermann & Cie GmbH, 5000 Köln Neue pflanzenschutzmittelsuspensionskonzentrate
US4675193A (en) * 1983-10-31 1987-06-23 Borden, Inc. Cheese-flavored substance and method of producing same
US4816247A (en) * 1985-09-11 1989-03-28 American Cyanamid Company Emulsion compositions for administration of sparingly water soluble ionizable hydrophobic drugs
US4874850A (en) 1986-08-07 1989-10-17 Medice Chem.-Pharm. Fabrik Putter Gmbh & Co. Pharmaceutical preparations
ATE115403T1 (de) 1987-01-27 1994-12-15 Vestar Inc Aus phospholipiden bestehende darreichungsform für wasserunlösliche wirksubstanzen.
EP0349150B1 (en) 1988-06-20 1994-08-17 Shiseido Company Limited Transparent compostition
EP0361928B1 (en) * 1988-09-29 1994-04-27 Shiseido Company Limited Emulsified composition
FR2648462B1 (fr) 1989-06-15 1994-01-28 Oreal Procede pour ameliorer l'efficacite therapeutique de corticosteroides liposolubles et composition pour la mise en oeuvre de ce procede
JP2785981B2 (ja) * 1989-11-20 1998-08-13 株式会社資生堂 乳化組成物
US5688761A (en) * 1991-04-19 1997-11-18 Lds Technologies, Inc. Convertible microemulsion formulations
WO1992018147A1 (en) * 1991-04-19 1992-10-29 Affinity Biotech, Inc. Convertible microemulsion formulations
ATE144137T1 (de) * 1991-07-26 1996-11-15 Smithkline Beecham Corp W/o mikroemulsionen
US5260065A (en) 1991-09-17 1993-11-09 Micro Vesicular Systems, Inc. Blended lipid vesicles
IL101007A (en) * 1992-02-18 1997-08-14 Pharmos Ltd Dry stable compositions prepared by lyophilization
IL101387A (en) 1992-03-26 1999-11-30 Pharmos Ltd Emulsion with enhanced topical and/or transdermal systemic effect utilizing submicron oil droplets
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
CH685674A5 (de) 1993-12-19 1995-09-15 Marigen Sa Ultramikroemulsionen aus spontan dispergierbaren Konzentraten mit pharmakologisch wirksamen Estern von Apocarotinolen.
IL115742A (en) * 1994-10-26 2000-06-01 Novartis Ag Pharmaceutical compositions comprising a difficultly soluble active agent a hydrophilic phase a lipophilic phase and a surfactant
EP0711556A1 (de) * 1994-11-09 1996-05-15 Ciba-Geigy Ag Intravenöse Lösungen für ein Staurosporinderivat
EP0733372A3 (de) * 1995-03-21 1998-05-20 Ciba-Geigy Ag Pharmazeutische Formulierungsgrundlage für Nanosuspensionen
WO1996037192A1 (en) * 1995-05-26 1996-11-28 Vesifact Ag Pharmaceutical and cosmetic compositions containing sphingo- and glycolipids
DE19522693A1 (de) 1995-06-22 1997-01-02 Dianorm G Maierhofer Gmbh Zusammensetzung zur Herstellung feindisperser Systeme und Verfahren zu ihrer Herstellung
JP3508314B2 (ja) * 1995-08-18 2004-03-22 大正製薬株式会社 ビタミンｃを配合した液剤
WO1997021428A1 (de) * 1995-12-12 1997-06-19 Vesifact Ag Cortisolspray zur topischen verabreichung
US6245349B1 (en) * 1996-02-23 2001-06-12 éLAN CORPORATION PLC Drug delivery compositions suitable for intravenous injection
ES2200144T3 (es) * 1996-12-13 2004-03-01 Vesifact Ag Preparaciones cosmeticas.
US6028067A (en) * 1997-12-05 2000-02-22 Chong Kun Dang Corp. Cyclosporin-containing microemulsion preconcentrate composition

Also Published As

Publication number Publication date
EP0956853A2 (de) 1999-11-17
EP0956853B1 (de) 2005-12-14
JP4755742B2 (ja) 2011-08-24
BRPI9902068B8 (pt) 2021-05-25
ES2253871T3 (es) 2006-06-01
SG71923A1 (en) 2000-04-18
HU9901570D0 (en) 1999-07-28
CN1235017A (zh) 1999-11-17
AU767896B2 (en) 2003-11-27
CZ166999A3 (cs) 1999-11-17
BR9902068A (pt) 2000-06-06
US20030190347A1 (en) 2003-10-09
KR100622285B1 (ko) 2006-09-11
HUP9901570A2 (hu) 2001-06-28
AU2805099A (en) 1999-11-18
TWI241915B (en) 2005-10-21
CN1220483C (zh) 2005-09-28
ID22565A (id) 1999-11-11
JPH11335266A (ja) 1999-12-07
US7871642B2 (en) 2011-01-18
BR9902068B1 (pt) 2014-10-29
RU2224505C2 (ru) 2004-02-27
PL332934A1 (en) 1999-11-22
EP0956853A3 (de) 2000-01-05
KR19990088156A (ko) 1999-12-27
US20060292191A1 (en) 2006-12-28
ATE312597T1 (de) 2005-12-15
AR019274A1 (es) 2002-02-13
US7081253B2 (en) 2006-07-25
MY133019A (en) 2007-10-31
DE59912910D1 (de) 2006-01-19

Similar Documents

Publication Publication Date Title
ZA993200B (en) Use of nanodispersions in pharmaceutical end formulations.
ZA993201B (en) Use of nanodispersions in cosmetic end formulations.
SG79255A1 (en) Pharmaceutical formulations
HK1061037A1 (en) Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same
IL147756A0 (en) Preserved pharmaceutical formulations
HK1045804A1 (en) Improved pharmaceutical formulations comprising ritonavir
HK1040488A1 (en) Pharmaceutical formulations.
EP1173216A4 (en) PHARMACEUTICAL FORMULATIONS
HUP0102226A3 (en) Hyperforin derivatives, the use thereof and formulations containing them
GB9818927D0 (en) Pharmaceutical formulation
GB9906126D0 (en) Pharmaceutical formulations
GB9930578D0 (en) Pharmaceutical formulations
GB9817470D0 (en) Pharmaceutical formulation
GB9802617D0 (en) Pharmaceutical formulation
EP1414417A4 (en) PHARMACEUTICAL FORMULATION
GB9825117D0 (en) Pharmaceutical formulations
GB9817429D0 (en) Pharmaceutical formulations
GB9828205D0 (en) Pharmaceutical formulations
GB9807556D0 (en) Pharmaceutical formulations
GB9813452D0 (en) Pharmaceutical formulations
GB9816558D0 (en) Pharmaceutical formulations
GB9820837D0 (en) Pharmaceutical formulations
GB9823192D0 (en) Pharmaceutical formulations
GB9826392D0 (en) Pharmaceutical formulations
GB9805931D0 (en) Pharmaceutical formulations